Global Ustekinumab Biosimilars Market Growth 2026-2032
The global Ustekinumab Biosimilars market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Ustekinumab biosimilars are drugs designed to closely replicate the structure and function of ustekinumab,a monoclonal antibody used to treat autoimmune conditions like psoriasis,Crohn's disease,and psoriatic arthritis.
United States market for Ustekinumab Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Ustekinumab Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Ustekinumab Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Ustekinumab Biosimilars players cover Teva, Amgen, Samsung Bioepis, Sandoz, Biocon Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Ustekinumab Biosimilars Industry Forecast” looks at past sales and reviews total world Ustekinumab Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Ustekinumab Biosimilars sales for 2026 through 2032. With Ustekinumab Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ustekinumab Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Ustekinumab Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ustekinumab Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ustekinumab Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ustekinumab Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ustekinumab Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Ustekinumab Biosimilars market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Ustekinumab Biosimilars market?
What factors are driving Ustekinumab Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ustekinumab Biosimilars market opportunities vary by end market size?
How does Ustekinumab Biosimilars break out by Type, by Application?
Ustekinumab biosimilars are drugs designed to closely replicate the structure and function of ustekinumab,a monoclonal antibody used to treat autoimmune conditions like psoriasis,Crohn's disease,and psoriatic arthritis.
United States market for Ustekinumab Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Ustekinumab Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Ustekinumab Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Ustekinumab Biosimilars players cover Teva, Amgen, Samsung Bioepis, Sandoz, Biocon Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Ustekinumab Biosimilars Industry Forecast” looks at past sales and reviews total world Ustekinumab Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Ustekinumab Biosimilars sales for 2026 through 2032. With Ustekinumab Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ustekinumab Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Ustekinumab Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ustekinumab Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ustekinumab Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ustekinumab Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ustekinumab Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Ustekinumab Biosimilars market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Subcutaneous Injection
- Intravenous Infusion
- Crohn's Disease
- Ulcerative Colitis
- Plaque Psoriasis
- Psoriatic Arthritis
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Teva
- Amgen
- Samsung Bioepis
- Sandoz
- Biocon Biologics
- Celltrion
- Qyuns Therapeutics
- Bio-Thera Solutions
- Huadong Medicine
What is the 10-year outlook for the global Ustekinumab Biosimilars market?
What factors are driving Ustekinumab Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ustekinumab Biosimilars market opportunities vary by end market size?
How does Ustekinumab Biosimilars break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ustekinumab Biosimilars Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Ustekinumab Biosimilars by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Ustekinumab Biosimilars by Country/Region, 2021, 2025 & 2032
2.2 Ustekinumab Biosimilars Segment by Type
2.2.1 Subcutaneous Injection
2.2.2 Intravenous Infusion
2.2.3 Ustekinumab Biosimilars Sales by Type
2.2.3.1 Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
2.2.3.2 Global Ustekinumab Biosimilars Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Ustekinumab Biosimilars Sale Price by Type (2021-2026)
2.3 Ustekinumab Biosimilars Segment by Application
2.3.1 Crohn's Disease
2.3.2 Ulcerative Colitis
2.3.3 Plaque Psoriasis
2.3.4 Psoriatic Arthritis
2.3.5 Other
2.3.6 Ustekinumab Biosimilars Sales by Application
2.3.6.1 Global Ustekinumab Biosimilars Sale Market Share by Application (2021-2026)
2.3.6.2 Global Ustekinumab Biosimilars Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Ustekinumab Biosimilars Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Ustekinumab Biosimilars Breakdown Data by Company
3.1.1 Global Ustekinumab Biosimilars Annual Sales by Company (2021-2026)
3.1.2 Global Ustekinumab Biosimilars Sales Market Share by Company (2021-2026)
3.2 Global Ustekinumab Biosimilars Annual Revenue by Company (2021-2026)
3.2.1 Global Ustekinumab Biosimilars Revenue by Company (2021-2026)
3.2.2 Global Ustekinumab Biosimilars Revenue Market Share by Company (2021-2026)
3.3 Global Ustekinumab Biosimilars Sale Price by Company
3.4 Key Manufacturers Ustekinumab Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ustekinumab Biosimilars Product Location Distribution
3.4.2 Players Ustekinumab Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR USTEKINUMAB BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Ustekinumab Biosimilars Market Size by Geographic Region (2021-2026)
4.1.1 Global Ustekinumab Biosimilars Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Ustekinumab Biosimilars Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Ustekinumab Biosimilars Market Size by Country/Region (2021-2026)
4.2.1 Global Ustekinumab Biosimilars Annual Sales by Country/Region (2021-2026)
4.2.2 Global Ustekinumab Biosimilars Annual Revenue by Country/Region (2021-2026)
4.3 Americas Ustekinumab Biosimilars Sales Growth
4.4 APAC Ustekinumab Biosimilars Sales Growth
4.5 Europe Ustekinumab Biosimilars Sales Growth
4.6 Middle East & Africa Ustekinumab Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Ustekinumab Biosimilars Sales by Country
5.1.1 Americas Ustekinumab Biosimilars Sales by Country (2021-2026)
5.1.2 Americas Ustekinumab Biosimilars Revenue by Country (2021-2026)
5.2 Americas Ustekinumab Biosimilars Sales by Type (2021-2026)
5.3 Americas Ustekinumab Biosimilars Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ustekinumab Biosimilars Sales by Region
6.1.1 APAC Ustekinumab Biosimilars Sales by Region (2021-2026)
6.1.2 APAC Ustekinumab Biosimilars Revenue by Region (2021-2026)
6.2 APAC Ustekinumab Biosimilars Sales by Type (2021-2026)
6.3 APAC Ustekinumab Biosimilars Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ustekinumab Biosimilars by Country
7.1.1 Europe Ustekinumab Biosimilars Sales by Country (2021-2026)
7.1.2 Europe Ustekinumab Biosimilars Revenue by Country (2021-2026)
7.2 Europe Ustekinumab Biosimilars Sales by Type (2021-2026)
7.3 Europe Ustekinumab Biosimilars Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ustekinumab Biosimilars by Country
8.1.1 Middle East & Africa Ustekinumab Biosimilars Sales by Country (2021-2026)
8.1.2 Middle East & Africa Ustekinumab Biosimilars Revenue by Country (2021-2026)
8.2 Middle East & Africa Ustekinumab Biosimilars Sales by Type (2021-2026)
8.3 Middle East & Africa Ustekinumab Biosimilars Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ustekinumab Biosimilars
10.3 Manufacturing Process Analysis of Ustekinumab Biosimilars
10.4 Industry Chain Structure of Ustekinumab Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ustekinumab Biosimilars Distributors
11.3 Ustekinumab Biosimilars Customer
12 WORLD FORECAST REVIEW FOR USTEKINUMAB BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Ustekinumab Biosimilars Market Size Forecast by Region
12.1.1 Global Ustekinumab Biosimilars Forecast by Region (2027-2032)
12.1.2 Global Ustekinumab Biosimilars Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Ustekinumab Biosimilars Forecast by Type (2027-2032)
12.7 Global Ustekinumab Biosimilars Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Teva
13.1.1 Teva Company Information
13.1.2 Teva Ustekinumab Biosimilars Product Portfolios and Specifications
13.1.3 Teva Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Teva Main Business Overview
13.1.5 Teva Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Ustekinumab Biosimilars Product Portfolios and Specifications
13.2.3 Amgen Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Samsung Bioepis
13.3.1 Samsung Bioepis Company Information
13.3.2 Samsung Bioepis Ustekinumab Biosimilars Product Portfolios and Specifications
13.3.3 Samsung Bioepis Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Samsung Bioepis Main Business Overview
13.3.5 Samsung Bioepis Latest Developments
13.4 Sandoz
13.4.1 Sandoz Company Information
13.4.2 Sandoz Ustekinumab Biosimilars Product Portfolios and Specifications
13.4.3 Sandoz Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sandoz Main Business Overview
13.4.5 Sandoz Latest Developments
13.5 Biocon Biologics
13.5.1 Biocon Biologics Company Information
13.5.2 Biocon Biologics Ustekinumab Biosimilars Product Portfolios and Specifications
13.5.3 Biocon Biologics Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Biocon Biologics Main Business Overview
13.5.5 Biocon Biologics Latest Developments
13.6 Celltrion
13.6.1 Celltrion Company Information
13.6.2 Celltrion Ustekinumab Biosimilars Product Portfolios and Specifications
13.6.3 Celltrion Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Celltrion Main Business Overview
13.6.5 Celltrion Latest Developments
13.7 Qyuns Therapeutics
13.7.1 Qyuns Therapeutics Company Information
13.7.2 Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolios and Specifications
13.7.3 Qyuns Therapeutics Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Qyuns Therapeutics Main Business Overview
13.7.5 Qyuns Therapeutics Latest Developments
13.8 Bio-Thera Solutions
13.8.1 Bio-Thera Solutions Company Information
13.8.2 Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolios and Specifications
13.8.3 Bio-Thera Solutions Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bio-Thera Solutions Main Business Overview
13.8.5 Bio-Thera Solutions Latest Developments
13.9 Huadong Medicine
13.9.1 Huadong Medicine Company Information
13.9.2 Huadong Medicine Ustekinumab Biosimilars Product Portfolios and Specifications
13.9.3 Huadong Medicine Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Huadong Medicine Main Business Overview
13.9.5 Huadong Medicine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ustekinumab Biosimilars Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Ustekinumab Biosimilars by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Ustekinumab Biosimilars by Country/Region, 2021, 2025 & 2032
2.2 Ustekinumab Biosimilars Segment by Type
2.2.1 Subcutaneous Injection
2.2.2 Intravenous Infusion
2.2.3 Ustekinumab Biosimilars Sales by Type
2.2.3.1 Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
2.2.3.2 Global Ustekinumab Biosimilars Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Ustekinumab Biosimilars Sale Price by Type (2021-2026)
2.3 Ustekinumab Biosimilars Segment by Application
2.3.1 Crohn's Disease
2.3.2 Ulcerative Colitis
2.3.3 Plaque Psoriasis
2.3.4 Psoriatic Arthritis
2.3.5 Other
2.3.6 Ustekinumab Biosimilars Sales by Application
2.3.6.1 Global Ustekinumab Biosimilars Sale Market Share by Application (2021-2026)
2.3.6.2 Global Ustekinumab Biosimilars Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Ustekinumab Biosimilars Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Ustekinumab Biosimilars Breakdown Data by Company
3.1.1 Global Ustekinumab Biosimilars Annual Sales by Company (2021-2026)
3.1.2 Global Ustekinumab Biosimilars Sales Market Share by Company (2021-2026)
3.2 Global Ustekinumab Biosimilars Annual Revenue by Company (2021-2026)
3.2.1 Global Ustekinumab Biosimilars Revenue by Company (2021-2026)
3.2.2 Global Ustekinumab Biosimilars Revenue Market Share by Company (2021-2026)
3.3 Global Ustekinumab Biosimilars Sale Price by Company
3.4 Key Manufacturers Ustekinumab Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ustekinumab Biosimilars Product Location Distribution
3.4.2 Players Ustekinumab Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR USTEKINUMAB BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Ustekinumab Biosimilars Market Size by Geographic Region (2021-2026)
4.1.1 Global Ustekinumab Biosimilars Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Ustekinumab Biosimilars Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Ustekinumab Biosimilars Market Size by Country/Region (2021-2026)
4.2.1 Global Ustekinumab Biosimilars Annual Sales by Country/Region (2021-2026)
4.2.2 Global Ustekinumab Biosimilars Annual Revenue by Country/Region (2021-2026)
4.3 Americas Ustekinumab Biosimilars Sales Growth
4.4 APAC Ustekinumab Biosimilars Sales Growth
4.5 Europe Ustekinumab Biosimilars Sales Growth
4.6 Middle East & Africa Ustekinumab Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Ustekinumab Biosimilars Sales by Country
5.1.1 Americas Ustekinumab Biosimilars Sales by Country (2021-2026)
5.1.2 Americas Ustekinumab Biosimilars Revenue by Country (2021-2026)
5.2 Americas Ustekinumab Biosimilars Sales by Type (2021-2026)
5.3 Americas Ustekinumab Biosimilars Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ustekinumab Biosimilars Sales by Region
6.1.1 APAC Ustekinumab Biosimilars Sales by Region (2021-2026)
6.1.2 APAC Ustekinumab Biosimilars Revenue by Region (2021-2026)
6.2 APAC Ustekinumab Biosimilars Sales by Type (2021-2026)
6.3 APAC Ustekinumab Biosimilars Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ustekinumab Biosimilars by Country
7.1.1 Europe Ustekinumab Biosimilars Sales by Country (2021-2026)
7.1.2 Europe Ustekinumab Biosimilars Revenue by Country (2021-2026)
7.2 Europe Ustekinumab Biosimilars Sales by Type (2021-2026)
7.3 Europe Ustekinumab Biosimilars Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ustekinumab Biosimilars by Country
8.1.1 Middle East & Africa Ustekinumab Biosimilars Sales by Country (2021-2026)
8.1.2 Middle East & Africa Ustekinumab Biosimilars Revenue by Country (2021-2026)
8.2 Middle East & Africa Ustekinumab Biosimilars Sales by Type (2021-2026)
8.3 Middle East & Africa Ustekinumab Biosimilars Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ustekinumab Biosimilars
10.3 Manufacturing Process Analysis of Ustekinumab Biosimilars
10.4 Industry Chain Structure of Ustekinumab Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ustekinumab Biosimilars Distributors
11.3 Ustekinumab Biosimilars Customer
12 WORLD FORECAST REVIEW FOR USTEKINUMAB BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Ustekinumab Biosimilars Market Size Forecast by Region
12.1.1 Global Ustekinumab Biosimilars Forecast by Region (2027-2032)
12.1.2 Global Ustekinumab Biosimilars Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Ustekinumab Biosimilars Forecast by Type (2027-2032)
12.7 Global Ustekinumab Biosimilars Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Teva
13.1.1 Teva Company Information
13.1.2 Teva Ustekinumab Biosimilars Product Portfolios and Specifications
13.1.3 Teva Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Teva Main Business Overview
13.1.5 Teva Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Ustekinumab Biosimilars Product Portfolios and Specifications
13.2.3 Amgen Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Samsung Bioepis
13.3.1 Samsung Bioepis Company Information
13.3.2 Samsung Bioepis Ustekinumab Biosimilars Product Portfolios and Specifications
13.3.3 Samsung Bioepis Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Samsung Bioepis Main Business Overview
13.3.5 Samsung Bioepis Latest Developments
13.4 Sandoz
13.4.1 Sandoz Company Information
13.4.2 Sandoz Ustekinumab Biosimilars Product Portfolios and Specifications
13.4.3 Sandoz Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sandoz Main Business Overview
13.4.5 Sandoz Latest Developments
13.5 Biocon Biologics
13.5.1 Biocon Biologics Company Information
13.5.2 Biocon Biologics Ustekinumab Biosimilars Product Portfolios and Specifications
13.5.3 Biocon Biologics Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Biocon Biologics Main Business Overview
13.5.5 Biocon Biologics Latest Developments
13.6 Celltrion
13.6.1 Celltrion Company Information
13.6.2 Celltrion Ustekinumab Biosimilars Product Portfolios and Specifications
13.6.3 Celltrion Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Celltrion Main Business Overview
13.6.5 Celltrion Latest Developments
13.7 Qyuns Therapeutics
13.7.1 Qyuns Therapeutics Company Information
13.7.2 Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolios and Specifications
13.7.3 Qyuns Therapeutics Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Qyuns Therapeutics Main Business Overview
13.7.5 Qyuns Therapeutics Latest Developments
13.8 Bio-Thera Solutions
13.8.1 Bio-Thera Solutions Company Information
13.8.2 Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolios and Specifications
13.8.3 Bio-Thera Solutions Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bio-Thera Solutions Main Business Overview
13.8.5 Bio-Thera Solutions Latest Developments
13.9 Huadong Medicine
13.9.1 Huadong Medicine Company Information
13.9.2 Huadong Medicine Ustekinumab Biosimilars Product Portfolios and Specifications
13.9.3 Huadong Medicine Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Huadong Medicine Main Business Overview
13.9.5 Huadong Medicine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Ustekinumab Biosimilars Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Ustekinumab Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Subcutaneous Injection
Table 4. Major Players of Intravenous Infusion
Table 5. Global Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 6. Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Table 7. Global Ustekinumab Biosimilars Revenue by Type (2021-2026) & ($ million)
Table 8. Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2026)
Table 9. Global Ustekinumab Biosimilars Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Ustekinumab Biosimilars Sale by Application (2021-2026) & (K Units)
Table 11. Global Ustekinumab Biosimilars Sale Market Share by Application (2021-2026)
Table 12. Global Ustekinumab Biosimilars Revenue by Application (2021-2026) & ($ million)
Table 13. Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2026)
Table 14. Global Ustekinumab Biosimilars Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Ustekinumab Biosimilars Sales by Company (2021-2026) & (K Units)
Table 16. Global Ustekinumab Biosimilars Sales Market Share by Company (2021-2026)
Table 17. Global Ustekinumab Biosimilars Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Ustekinumab Biosimilars Revenue Market Share by Company (2021-2026)
Table 19. Global Ustekinumab Biosimilars Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Ustekinumab Biosimilars Producing Area Distribution and Sales Area
Table 21. Players Ustekinumab Biosimilars Products Offered
Table 22. Ustekinumab Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Ustekinumab Biosimilars Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Ustekinumab Biosimilars Sales Market Share Geographic Region (2021-2026)
Table 27. Global Ustekinumab Biosimilars Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Ustekinumab Biosimilars Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Ustekinumab Biosimilars Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Ustekinumab Biosimilars Sales Market Share by Country/Region (2021-2026)
Table 31. Global Ustekinumab Biosimilars Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Ustekinumab Biosimilars Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units)
Table 34. Americas Ustekinumab Biosimilars Sales Market Share by Country (2021-2026)
Table 35. Americas Ustekinumab Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 37. Americas Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units)
Table 38. APAC Ustekinumab Biosimilars Sales by Region (2021-2026) & (K Units)
Table 39. APAC Ustekinumab Biosimilars Sales Market Share by Region (2021-2026)
Table 40. APAC Ustekinumab Biosimilars Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 42. APAC Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units)
Table 43. Europe Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units)
Table 44. Europe Ustekinumab Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 46. Europe Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Ustekinumab Biosimilars Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Ustekinumab Biosimilars
Table 52. Key Market Challenges & Risks of Ustekinumab Biosimilars
Table 53. Key Industry Trends of Ustekinumab Biosimilars
Table 54. Ustekinumab Biosimilars Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Ustekinumab Biosimilars Distributors List
Table 57. Ustekinumab Biosimilars Customer List
Table 58. Global Ustekinumab Biosimilars Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Ustekinumab Biosimilars Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Ustekinumab Biosimilars Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Ustekinumab Biosimilars Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Ustekinumab Biosimilars Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Ustekinumab Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Ustekinumab Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Ustekinumab Biosimilars Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Ustekinumab Biosimilars Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Ustekinumab Biosimilars Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Ustekinumab Biosimilars Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Teva Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 73. Teva Ustekinumab Biosimilars Product Portfolios and Specifications
Table 74. Teva Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Teva Main Business
Table 76. Teva Latest Developments
Table 77. Amgen Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Ustekinumab Biosimilars Product Portfolios and Specifications
Table 79. Amgen Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Samsung Bioepis Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 83. Samsung Bioepis Ustekinumab Biosimilars Product Portfolios and Specifications
Table 84. Samsung Bioepis Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Samsung Bioepis Main Business
Table 86. Samsung Bioepis Latest Developments
Table 87. Sandoz Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 88. Sandoz Ustekinumab Biosimilars Product Portfolios and Specifications
Table 89. Sandoz Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Sandoz Main Business
Table 91. Sandoz Latest Developments
Table 92. Biocon Biologics Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 93. Biocon Biologics Ustekinumab Biosimilars Product Portfolios and Specifications
Table 94. Biocon Biologics Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Biocon Biologics Main Business
Table 96. Biocon Biologics Latest Developments
Table 97. Celltrion Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 98. Celltrion Ustekinumab Biosimilars Product Portfolios and Specifications
Table 99. Celltrion Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Celltrion Main Business
Table 101. Celltrion Latest Developments
Table 102. Qyuns Therapeutics Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 103. Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolios and Specifications
Table 104. Qyuns Therapeutics Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Qyuns Therapeutics Main Business
Table 106. Qyuns Therapeutics Latest Developments
Table 107. Bio-Thera Solutions Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 108. Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolios and Specifications
Table 109. Bio-Thera Solutions Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Bio-Thera Solutions Main Business
Table 111. Bio-Thera Solutions Latest Developments
Table 112. Huadong Medicine Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 113. Huadong Medicine Ustekinumab Biosimilars Product Portfolios and Specifications
Table 114. Huadong Medicine Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Huadong Medicine Main Business
Table 116. Huadong Medicine Latest Developments
Table 1. Ustekinumab Biosimilars Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Ustekinumab Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Subcutaneous Injection
Table 4. Major Players of Intravenous Infusion
Table 5. Global Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 6. Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Table 7. Global Ustekinumab Biosimilars Revenue by Type (2021-2026) & ($ million)
Table 8. Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2026)
Table 9. Global Ustekinumab Biosimilars Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Ustekinumab Biosimilars Sale by Application (2021-2026) & (K Units)
Table 11. Global Ustekinumab Biosimilars Sale Market Share by Application (2021-2026)
Table 12. Global Ustekinumab Biosimilars Revenue by Application (2021-2026) & ($ million)
Table 13. Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2026)
Table 14. Global Ustekinumab Biosimilars Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Ustekinumab Biosimilars Sales by Company (2021-2026) & (K Units)
Table 16. Global Ustekinumab Biosimilars Sales Market Share by Company (2021-2026)
Table 17. Global Ustekinumab Biosimilars Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Ustekinumab Biosimilars Revenue Market Share by Company (2021-2026)
Table 19. Global Ustekinumab Biosimilars Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Ustekinumab Biosimilars Producing Area Distribution and Sales Area
Table 21. Players Ustekinumab Biosimilars Products Offered
Table 22. Ustekinumab Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Ustekinumab Biosimilars Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Ustekinumab Biosimilars Sales Market Share Geographic Region (2021-2026)
Table 27. Global Ustekinumab Biosimilars Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Ustekinumab Biosimilars Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Ustekinumab Biosimilars Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Ustekinumab Biosimilars Sales Market Share by Country/Region (2021-2026)
Table 31. Global Ustekinumab Biosimilars Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Ustekinumab Biosimilars Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units)
Table 34. Americas Ustekinumab Biosimilars Sales Market Share by Country (2021-2026)
Table 35. Americas Ustekinumab Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 37. Americas Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units)
Table 38. APAC Ustekinumab Biosimilars Sales by Region (2021-2026) & (K Units)
Table 39. APAC Ustekinumab Biosimilars Sales Market Share by Region (2021-2026)
Table 40. APAC Ustekinumab Biosimilars Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 42. APAC Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units)
Table 43. Europe Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units)
Table 44. Europe Ustekinumab Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 46. Europe Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Ustekinumab Biosimilars Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Ustekinumab Biosimilars
Table 52. Key Market Challenges & Risks of Ustekinumab Biosimilars
Table 53. Key Industry Trends of Ustekinumab Biosimilars
Table 54. Ustekinumab Biosimilars Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Ustekinumab Biosimilars Distributors List
Table 57. Ustekinumab Biosimilars Customer List
Table 58. Global Ustekinumab Biosimilars Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Ustekinumab Biosimilars Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Ustekinumab Biosimilars Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Ustekinumab Biosimilars Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Ustekinumab Biosimilars Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Ustekinumab Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Ustekinumab Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Ustekinumab Biosimilars Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Ustekinumab Biosimilars Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Ustekinumab Biosimilars Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Ustekinumab Biosimilars Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Teva Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 73. Teva Ustekinumab Biosimilars Product Portfolios and Specifications
Table 74. Teva Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Teva Main Business
Table 76. Teva Latest Developments
Table 77. Amgen Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Ustekinumab Biosimilars Product Portfolios and Specifications
Table 79. Amgen Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Samsung Bioepis Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 83. Samsung Bioepis Ustekinumab Biosimilars Product Portfolios and Specifications
Table 84. Samsung Bioepis Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Samsung Bioepis Main Business
Table 86. Samsung Bioepis Latest Developments
Table 87. Sandoz Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 88. Sandoz Ustekinumab Biosimilars Product Portfolios and Specifications
Table 89. Sandoz Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Sandoz Main Business
Table 91. Sandoz Latest Developments
Table 92. Biocon Biologics Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 93. Biocon Biologics Ustekinumab Biosimilars Product Portfolios and Specifications
Table 94. Biocon Biologics Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Biocon Biologics Main Business
Table 96. Biocon Biologics Latest Developments
Table 97. Celltrion Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 98. Celltrion Ustekinumab Biosimilars Product Portfolios and Specifications
Table 99. Celltrion Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Celltrion Main Business
Table 101. Celltrion Latest Developments
Table 102. Qyuns Therapeutics Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 103. Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolios and Specifications
Table 104. Qyuns Therapeutics Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Qyuns Therapeutics Main Business
Table 106. Qyuns Therapeutics Latest Developments
Table 107. Bio-Thera Solutions Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 108. Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolios and Specifications
Table 109. Bio-Thera Solutions Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Bio-Thera Solutions Main Business
Table 111. Bio-Thera Solutions Latest Developments
Table 112. Huadong Medicine Basic Information, Ustekinumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 113. Huadong Medicine Ustekinumab Biosimilars Product Portfolios and Specifications
Table 114. Huadong Medicine Ustekinumab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Huadong Medicine Main Business
Table 116. Huadong Medicine Latest Developments
LIST OF FIGURES
Figure 1. Picture of Ustekinumab Biosimilars
Figure 2. Ustekinumab Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ustekinumab Biosimilars Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Ustekinumab Biosimilars Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Ustekinumab Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Ustekinumab Biosimilars Sales Market Share by Country/Region (2025)
Figure 10. Ustekinumab Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Subcutaneous Injection
Figure 12. Product Picture of Intravenous Infusion
Figure 13. Global Ustekinumab Biosimilars Sales Market Share by Type in 2026
Figure 14. Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2026)
Figure 15. Ustekinumab Biosimilars Consumed in Crohn's Disease
Figure 16. Global Ustekinumab Biosimilars Market: Crohn's Disease (2021-2026) & (K Units)
Figure 17. Ustekinumab Biosimilars Consumed in Ulcerative Colitis
Figure 18. Global Ustekinumab Biosimilars Market: Ulcerative Colitis (2021-2026) & (K Units)
Figure 19. Ustekinumab Biosimilars Consumed in Plaque Psoriasis
Figure 20. Global Ustekinumab Biosimilars Market: Plaque Psoriasis (2021-2026) & (K Units)
Figure 21. Ustekinumab Biosimilars Consumed in Psoriatic Arthritis
Figure 22. Global Ustekinumab Biosimilars Market: Psoriatic Arthritis (2021-2026) & (K Units)
Figure 23. Ustekinumab Biosimilars Consumed in Other
Figure 24. Global Ustekinumab Biosimilars Market: Other (2021-2026) & (K Units)
Figure 25. Global Ustekinumab Biosimilars Sale Market Share by Application (2025)
Figure 26. Global Ustekinumab Biosimilars Revenue Market Share by Application in 2026
Figure 27. Ustekinumab Biosimilars Sales by Company in 2026 (K Units)
Figure 28. Global Ustekinumab Biosimilars Sales Market Share by Company in 2026
Figure 29. Ustekinumab Biosimilars Revenue by Company in 2026 ($ millions)
Figure 30. Global Ustekinumab Biosimilars Revenue Market Share by Company in 2026
Figure 31. Global Ustekinumab Biosimilars Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Ustekinumab Biosimilars Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Ustekinumab Biosimilars Sales 2021-2026 (K Units)
Figure 34. Americas Ustekinumab Biosimilars Revenue 2021-2026 ($ millions)
Figure 35. APAC Ustekinumab Biosimilars Sales 2021-2026 (K Units)
Figure 36. APAC Ustekinumab Biosimilars Revenue 2021-2026 ($ millions)
Figure 37. Europe Ustekinumab Biosimilars Sales 2021-2026 (K Units)
Figure 38. Europe Ustekinumab Biosimilars Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Ustekinumab Biosimilars Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Ustekinumab Biosimilars Revenue 2021-2026 ($ millions)
Figure 41. Americas Ustekinumab Biosimilars Sales Market Share by Country in 2026
Figure 42. Americas Ustekinumab Biosimilars Revenue Market Share by Country (2021-2026)
Figure 43. Americas Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Figure 44. Americas Ustekinumab Biosimilars Sales Market Share by Application (2021-2026)
Figure 45. United States Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Ustekinumab Biosimilars Sales Market Share by Region in 2026
Figure 50. APAC Ustekinumab Biosimilars Revenue Market Share by Region (2021-2026)
Figure 51. APAC Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Figure 52. APAC Ustekinumab Biosimilars Sales Market Share by Application (2021-2026)
Figure 53. China Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 57. India Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Ustekinumab Biosimilars Sales Market Share by Country in 2026
Figure 61. Europe Ustekinumab Biosimilars Revenue Market Share by Country (2021-2026)
Figure 62. Europe Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Figure 63. Europe Ustekinumab Biosimilars Sales Market Share by Application (2021-2026)
Figure 64. Germany Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 65. France Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Ustekinumab Biosimilars Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Ustekinumab Biosimilars Sales Market Share by Application (2021-2026)
Figure 72. Egypt Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Ustekinumab Biosimilars in 2026
Figure 78. Manufacturing Process Analysis of Ustekinumab Biosimilars
Figure 79. Industry Chain Structure of Ustekinumab Biosimilars
Figure 80. Channels of Distribution
Figure 81. Global Ustekinumab Biosimilars Sales Market Forecast by Region (2027-2032)
Figure 82. Global Ustekinumab Biosimilars Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Ustekinumab Biosimilars Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Ustekinumab Biosimilars Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Ustekinumab Biosimilars Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Ustekinumab Biosimilars Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Ustekinumab Biosimilars
Figure 2. Ustekinumab Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ustekinumab Biosimilars Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Ustekinumab Biosimilars Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Ustekinumab Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Ustekinumab Biosimilars Sales Market Share by Country/Region (2025)
Figure 10. Ustekinumab Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Subcutaneous Injection
Figure 12. Product Picture of Intravenous Infusion
Figure 13. Global Ustekinumab Biosimilars Sales Market Share by Type in 2026
Figure 14. Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2026)
Figure 15. Ustekinumab Biosimilars Consumed in Crohn's Disease
Figure 16. Global Ustekinumab Biosimilars Market: Crohn's Disease (2021-2026) & (K Units)
Figure 17. Ustekinumab Biosimilars Consumed in Ulcerative Colitis
Figure 18. Global Ustekinumab Biosimilars Market: Ulcerative Colitis (2021-2026) & (K Units)
Figure 19. Ustekinumab Biosimilars Consumed in Plaque Psoriasis
Figure 20. Global Ustekinumab Biosimilars Market: Plaque Psoriasis (2021-2026) & (K Units)
Figure 21. Ustekinumab Biosimilars Consumed in Psoriatic Arthritis
Figure 22. Global Ustekinumab Biosimilars Market: Psoriatic Arthritis (2021-2026) & (K Units)
Figure 23. Ustekinumab Biosimilars Consumed in Other
Figure 24. Global Ustekinumab Biosimilars Market: Other (2021-2026) & (K Units)
Figure 25. Global Ustekinumab Biosimilars Sale Market Share by Application (2025)
Figure 26. Global Ustekinumab Biosimilars Revenue Market Share by Application in 2026
Figure 27. Ustekinumab Biosimilars Sales by Company in 2026 (K Units)
Figure 28. Global Ustekinumab Biosimilars Sales Market Share by Company in 2026
Figure 29. Ustekinumab Biosimilars Revenue by Company in 2026 ($ millions)
Figure 30. Global Ustekinumab Biosimilars Revenue Market Share by Company in 2026
Figure 31. Global Ustekinumab Biosimilars Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Ustekinumab Biosimilars Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Ustekinumab Biosimilars Sales 2021-2026 (K Units)
Figure 34. Americas Ustekinumab Biosimilars Revenue 2021-2026 ($ millions)
Figure 35. APAC Ustekinumab Biosimilars Sales 2021-2026 (K Units)
Figure 36. APAC Ustekinumab Biosimilars Revenue 2021-2026 ($ millions)
Figure 37. Europe Ustekinumab Biosimilars Sales 2021-2026 (K Units)
Figure 38. Europe Ustekinumab Biosimilars Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Ustekinumab Biosimilars Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Ustekinumab Biosimilars Revenue 2021-2026 ($ millions)
Figure 41. Americas Ustekinumab Biosimilars Sales Market Share by Country in 2026
Figure 42. Americas Ustekinumab Biosimilars Revenue Market Share by Country (2021-2026)
Figure 43. Americas Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Figure 44. Americas Ustekinumab Biosimilars Sales Market Share by Application (2021-2026)
Figure 45. United States Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Ustekinumab Biosimilars Sales Market Share by Region in 2026
Figure 50. APAC Ustekinumab Biosimilars Revenue Market Share by Region (2021-2026)
Figure 51. APAC Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Figure 52. APAC Ustekinumab Biosimilars Sales Market Share by Application (2021-2026)
Figure 53. China Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 57. India Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Ustekinumab Biosimilars Sales Market Share by Country in 2026
Figure 61. Europe Ustekinumab Biosimilars Revenue Market Share by Country (2021-2026)
Figure 62. Europe Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Figure 63. Europe Ustekinumab Biosimilars Sales Market Share by Application (2021-2026)
Figure 64. Germany Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 65. France Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Ustekinumab Biosimilars Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Ustekinumab Biosimilars Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Ustekinumab Biosimilars Sales Market Share by Application (2021-2026)
Figure 72. Egypt Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Ustekinumab Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Ustekinumab Biosimilars in 2026
Figure 78. Manufacturing Process Analysis of Ustekinumab Biosimilars
Figure 79. Industry Chain Structure of Ustekinumab Biosimilars
Figure 80. Channels of Distribution
Figure 81. Global Ustekinumab Biosimilars Sales Market Forecast by Region (2027-2032)
Figure 82. Global Ustekinumab Biosimilars Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Ustekinumab Biosimilars Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Ustekinumab Biosimilars Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Ustekinumab Biosimilars Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Ustekinumab Biosimilars Revenue Market Share Forecast by Application (2027-2032)
